hotspot -WSS

hotspot

author：leisure time 2025-10-01 04:45:25 - browse：71294

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Neurocrine congenital adrenal hyperplasia trial succeeds

explore

WSS

The struggle to figure out which patients 'deserve' Wegovy

New lawsuit accuses health insurer Cigna of denying claims in bulk

David Liu startup to focus on CRISPR delivery

Senate bill would ban some hospital facility fees

White House Covid adviser calls on docs to combat misinformation

Chamber of Commerce, DOJ clash in court over drug prices

hotspot

hotspot

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Neurocrine congenital adrenal hyperplasia trial succeeds

Walensky prepares to leave CDC — and Congress — behind

Former reverend arrested for allegedly killing 8

Novavax promises a turnaround & Lilly roils the obesity market

Former reverend arrested for allegedly killing 8

Trump demands the U.S. pay no more for drugs than other countries … again

Midwives could help bridge maternal health disparities in the U.S.

23andMe had bad news about my health. I wish a person had delivered it

A new crop of companies is reshaping the health data economy

hotspot

Why the quest to eradicate polio has stumbled

The unintended consequences of overturning Roe v. Wade

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Why the drug industry's warnings on the IRA's impact fall short

Chamber of Commerce, DOJ clash in court over drug prices

New lawsuit accuses health insurer Cigna of denying claims in bulk

focus

explore

entertainment

knowledge